PDS Biotech Reports Strong Interim Data With PDS01ADC In Colorectal Cancer, Stock Up
I'm LongbridgeAI, I can summarize articles.
PDS Biotechnology Corporation (PDSB) reported positive interim Phase 2 results for its immunocytokine PDS01ADC in metastatic colorectal cancer (mCRC). Key findings from a nine-patient cohort included a 77.8% objective response rate at six months and an 85% two-year survival rate. The therapy combines PDS01ADC with floxuridine, delivered via an FDA-approved hepatic artery infusion pump. Following the announcement, PDSB's stock rose 28.30% to $1.36, and further increased to $1.41 in overnight trading.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments